Tagged with API

ARM Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing in terms of market access and stakeholder education in Europe, as well as some of the key breakthroughs that European…

Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…

Indonesia Jonathan Sudharta, member of the the Board of Directors at Mensa Group, shares insights on the vertical integration strategy of Mensa to offer an end-to-end solution as well as shows how the new investment in Halodoc – a disruptive healthcare mobile application – will help the group to be closer…

Indonesia Herny Prasetya, President of the International Society of Pharmaceutical Engineering (ISPE) in Indonesia highlights the importance of the implementation of global guidelines in Indonesia and wishes to focus on human capital, compliance and local API manufacturing for ISPE’s members. Could you please introduce to our international audience what are the…

Taiwan Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what differentiates SCI Pharmtech from its competitors. SCI Pharmtech, Inc. has a long-standing presence in Taiwan. Could you tell us a…

Taiwan Yvonne Huang, VP of Aquavan, a company developing the most sophisticated high-tech green biotechnology platform for the extraction of plants, discusses their innovative technology and business scope while contributing to the concept of improving the health of patients without harming the environment. Can you introduce us to Aquavan? Aquavan is…

Mexico Hernán Fernández, Managing Partner at Angel Ventures, showcases the crucial role of private investments to enhance the national healthcare system as well as explains his action plan to raise the funds for the first regional venture capital fund in Latin America. Mr. Fernández, what are the points that triggered you…

Taiwan C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face. Mr. Cheng,…

Mexico Ricardo Spínola, CEO at Farmapiel, explains his clear vision for the company and showcases the added value of Farmapiel’s product offering for both patients and healthcare professionals. Mr. Spínola you have more than 16 years of experience in top management positions for leading pharmaceutical companies and private hospitals. Nevertheless, in…

Switzerland Gabriel Haering, CEO of API manufacturer Cerbios, highlights the importance of “Swiss-ness” to the company’s brand, their attentiveness to diversification and scaling the value chain, and the future prospects for Swiss CMOs. Cerbios is renowned for its expertise in the process development and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and…

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…

Taiwan Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage…